XXXX PET imaging in hepatocellular @entity96 .

@entity1 @entity419 @entity2695 @entity5 @entity96 @entity409 @entity201 @entity4383 @entity4303 @entity157 @entity652 @entity18808 @entity413
It is well known that @entity419 PET has a high average false-negative rate of 40%-50% in the @entity157 ( @entity157 ). This is not an acceptable accuracy, particularly in countries where this @entity5 is prevalent. In this study, we evaluated prospectively the characteristics of @entity18808 and @entity419 metabolism in @entity157 and other @entity409 . METHODS: Fifty-seven @entity1 were recruited into this study, with masses consisting of 39 @entity157 ; 3 @entity201 ; 10 hepatic metastases from lung, breast, colon, and @entity4303 primary @entity5 ; and 5 benign pathologies, including @entity4383 ( @entity4383 ), @entity652 , and @entity2695 . All @entity1 , except 2 with typical findings of @entity2695 and 3 clinically obvious metastases, were confirmed histopathologically by liver biopsy or resection. All @entity1 fasted for at least 6 h and blood @entity413 concentration was measured before they underwent dual PET radiopharmaceutical evaluation of the upper abdomen with @entity18808 and @entity419 . RESULTS: In the subgroup of @entity157 @entity1 with the number of lesions < or = 3 (32 @entity1 ; 55 lesions; mean size +/- SD, 3.5 +/- 1.9 cm), the sensitivity of detection by @entity18808 is 87.3% ((11)C-acetate maximum SUV [SUV(max)] = 7.32 +/- 2.02, with a lesion-to-normal liver ratio of 1.96 +/- 0.63), whereas the sensitivity of detection by @entity419 is only 47.3%, and 34% lesions show uptake of both tracers. None of the lesions was negative for both tracers (100% sensitivity using both tracers). In some lesions and in the subgroup of @entity157 @entity1 (n = 7) with multifocal or diffuse disease, dual-tracer uptake by different parts of the @entity5 is demonstrated. Histopathologic correlation suggests that the well-differentiated @entity96 are detected by @entity18808 and the poorly differentiated types are detected by @entity419 . All 16 non- @entity157 malignant ( @entity201 and metastatic) liver lesions do not show abnormal @entity18808 metabolism. Of the benign liver lesions, only @entity4383 shows mildly increased @entity18808 activities ( @entity18808 SUV(max) = 3.59, with a lesion-to-normal liver ratio of 1.25). CONCLUSION: @entity18808 has a high sensitivity and specificity as a radiotracer complementary to @entity419 in PET imaging of @entity157 and evaluation of other @entity409 .
